Treats major depressive disorder (MDD). Sold as Viibryd. Every FDA application for this active ingredient: 1 branded and 5 generic.
As of Nov 16, 2026, FDA lists 6 applications for Vilazodone Hydrochloride (sold as Viibryd), first approved Jan 21, 2011, with 2 new uses approved and 0 published complete response letters.
| Vilazodone HCl | Part D | $37.6M | 0% | 69,417 |
| Viibryd | Part D | $3.3M | -44% | 1,448 |
| Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life DepressionDepression · University of Illinois Chicago | Phase 2 | Recruiting | Sep 19, 2024 |
| Department of Defense PTSD Adaptive Platform Trial - Intervention B - VilazodonePost Traumatic Stress Disorder · Global Coalition for Adaptive Research | Phase 2 | Not yet recruiting | Jul 17, 2023 |
| Jan 21, 2011 | ViibrydNDA 22567 · New molecular entity | Abbvie | 19 | Marketed |
| Sep 30, 2019 | Vilazodone HydrochlorideANDA 208212 | Teva Pharms USA | 2 | Marketed |
| Jan 10, 2020 | Vilazodone HydrochlorideANDA 208202 | Alembic | 5 | Marketed |
| Apr 27, 2021 | Vilazodone HydrochlorideANDA 208209 | Accord Hlthcare | 3 | Marketed |
| Dec 6, 2022 | Vilazodone HydrochlorideANDA 208200 | Invagen Pharms | 2 | Marketed |
| Jul 7, 2023 | Vilazodone HydrochlorideANDA 208228 | Apotex | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA